University of Minnesota-MNCCTN013: Endocrine Therapy-Induced Alopecia Natural History Evaluation Among Female Breast Cancer Survivors

Objective

This study evaluates endocrine therapy-induced alopecia among postmenopausal and premenopausal female patients with breast cancer. Alopecia is one of the most feared side effects of cancer-directed therapy, causing distress in women starting treatment for breast cancer. While alopecia is a well-known side effect of many chemotherapy drugs, it has also been reported by women undergoing endocrine therapy. Despite the frequent reports of alopecia related to endocrine therapy, hair loss is rarely reported as a side effect of endocrine therapy and the exact characterization of alopecia is not well understood. By having postmenopausal and premenopausal breast cancer patients describe their hair loss symptoms experienced while undergoing endocrine therapy, researchers may be able to better characterize the incidence, timing, duration, and severity of alopecia and whether the different types of endocrine therapy cause more or less trouble in this regard.

National Clinical Trial (NCT) Number: 05612100

National Library of Medicine clinicaltrials.gov Website Address: https://clinicaltrials.gov/study/NCT05612100

Location: Essentia Health Cancer Centers

Research Study Categories

• Adult Oncology Studies

Specialties

• Breast Cancer

Contact

Cancer Clinical Trials at 218-786-3308 or 844-681-7944, [email protected]